Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells

References

• Mayr A, Hochstein-MintzeI V, Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection. 1975;3:6–14.
   Google Scholar
• Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997;238:198–211.
   PubMed Web of Science ®Google Scholar
• Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998;79:347–52.
   PubMed Web of Science ®Google Scholar
• Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991;72:1031–8.
   PubMed Web of Science ®Google Scholar
• Altenburger W, Suter CP, Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol. 1989;105:15–27.
   PubMed Web of Science ®Google Scholar
• Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology. 1998;244:365–96.
   PubMed Web of Science ®Google Scholar
• Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand. 1978;41: 225–34.
   PubMedGoogle Scholar
• Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author transl)]. Dtsch Med Wochenschr. 1974;99:2386–92.
   PubMed Web of Science ®Google Scholar
• Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author transl)]. Zentralbl Bakteriol [B]. 1978;167:375–90.
   PubMedGoogle Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA. 1992;89:10847–51.
   PubMed Web of Science ®Google Scholar
• Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, . Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008;26: 6883–93.
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, . Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007;25:2120–7.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, . Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2.
   PubMed Web of Science ®Google Scholar
• Dreicer R, Ahman R, Pantuck A, Stadler WM, Bizouarne N, Derbij BA, . Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure. ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23:4581.
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, . Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008; 57:977–86.
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, . A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3:735–44.
   PubMed Web of Science ®Google Scholar
• Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, . A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother. 2005;54:453–67.
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, . Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198:544–52.
   PubMed Web of Science ®Google Scholar
• Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, . Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine. 2007;25:8562–73.
   PubMed Web of Science ®Google Scholar
• Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, . Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007;25:1513–25.
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, . Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428:182–5.
   PubMed Web of Science ®Google Scholar
• Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schatzl H, . Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses. 2007;23:782–93.
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, . Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001;19:3700–9.
   PubMed Web of Science ®Google Scholar
• Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, . Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27:4468–74.
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, . Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292:69–74.
   PubMed Web of Science ®Google Scholar
• Chahroudi A, Chavan R, Kozyr N, Waller EK, Silvestri G, Feinberg MB. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol. 2005;79:10397–407.
   PubMed Web of Science ®Google Scholar
• Sanchez-Puig JM, Sanchez L, Roy G, Blasco R. Susceptibility of different leukocyte cell types to vaccinia virus infection. Virol J. 2004;1:10.
   PubMed Web of Science ®Google Scholar
• Liu L, Chavan R, Feinberg MB. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008;9:15.
   PubMed Web of Science ®Google Scholar
• Drillien R, Spehner D, Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol. 2004;85:2167–75.
   PubMed Web of Science ®Google Scholar
• Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, Gatell JM, . Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol. 2007;81:8707–21.
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol. 2009;83:2540–52.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, . A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 2006;46:2083–9.
   PubMed Web of Science ®Google Scholar
• Strasser EF, Weidinger T, Zimmermann R, Ringwald J, Eckstein R. Recovery of white blood cells and platelets from leukoreduction system chambers of Trima Accel and COBE Spectra plateletpheresis devices. Transfusion. 2007;47: 1943–5.
   PubMed Web of Science ®Google Scholar
• Neron S, Thibault L, Dussault N, Cote G, Ducas E, Pineault N, . Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells. Transfusion. 2007;47:1042–9.
   PubMed Web of Science ®Google Scholar
• Grigoleit GU, Kapp M, Hebart H, Fick K, Beck R, Jahn G, . Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis. 2007;196:699–704.
   PubMed Web of Science ®Google Scholar
• Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques. 2000;28: 1137–42, 44–6, 48.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 1996;14:1451–8.
   PubMed Web of Science ®Google Scholar
• Staib C, Lowel M, Erfle V, Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques. 2003;34:694–6, 8, 700.
   PubMed Web of Science ®Google Scholar
• Falkner FG, Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol. 1990;64:3108–11.
   PubMed Web of Science ®Google Scholar
• Loeffler J, Swatoch P, Akhawi-Araghi D, Hebart H, Einsele H. Automated RNA extraction by MagNA Pure followed by rapid quantification of cytokine and chemokine gene expression with use of fluorescence resonance energy transfer. Clin Chem. 2003;49:955–8.
   PubMed Web of Science ®Google Scholar
• Mezger M, Kneitz S, Wozniok I, Kurzai O, Einsele H, Loeffler J. Proinflammatory response of immature human dendritic cells is mediated by dectin-1 after exposure to Aspergillus fumigatus germ tubes. J Infect Dis. 2008;197:924–31.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, . Functional leukemia-associated antigen-specific memory CD8+T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102: 2892–900.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Lacey SF, Lalimarmo MM, Krishnan A, Longmate J, . In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol. 2006;34:497–507.
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol. 2007;81:11925–36.
   PubMed Web of Science ®Google Scholar
• Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol. 2006;146:344–53.
   PubMedGoogle Scholar
• Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol. 2000;74:923–33.
   PubMed Web of Science ®Google Scholar
• Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, . Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 2009;5:e1000480.
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557–69.
   PubMed Web of Science ®Google Scholar
• Snijders A, Hilkens CM, van der Pouw Kraan TC, Engel M, Aarden LA, Kapsenberg ML. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol. 1996;156:1207–12.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97: 3466–9.
   PubMed Web of Science ®Google Scholar
• Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, . Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995;154:116–27.
   PubMed Web of Science ®Google Scholar
• Mattner F, Fischer S, Guckes S, Jin S, Kaulen H, Schmitt E, . The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol. 1993;23:2202–8.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–25.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, . CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005;116:1372–9.
   PubMed Web of Science ®Google Scholar
• Boraschi D, Villa L, Volpini G, Bossu P, Censini S, Ghiara P, . Differential activity of interleukin 1 alpha and interleukin 1 beta in the stimulation of the immune response in vivo. Eur J Immunol. 1990;20:317–21.
   PubMed Web of Science ®Google Scholar
• Johnson VJ, Yucesoy B, Luster MI. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol. 2005;116:851–8.
   PubMed Web of Science ®Google Scholar
• Wang CC, Fu CL, Yang YH, Lo YC, Wang LC, Chuang YH, . Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther. 2006;13:1414–21.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Romagnani S. Do studies in humans better depict Th17 cells? Blood. 2009;114:2213–9.
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, . Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology. 2006;350: 276–88.
   Google Scholar
• Baixeras E, Cebrian A, Albar JP, Salas J, Martinez AC, Vinuela E, . Vaccinia virus-induced apoptosis in immature B lymphocytes: role of cellular Bcl-2. Virus Res. 1998; 58:107–13.
   PubMed Web of Science ®Google Scholar
• Norder M, Becker PD, Drexler I, Link C, Erfle V, Guzman CA. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One.5: e11400.
   Google Scholar